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Abstract
Background: Gain-of-function of erythropoietin receptor (EPOR) mutations represent the major cause of primary hereditary
polycythemia. EPOR is also found in non-erythroid tissues, although its physiological role is still undefined.
Methodology/Principal Findings: We describe a family with polycythemia due to a heterozygous mutation of the EPOR
gene that causes a GRT change at nucleotide 1251 of exon 8. The novel EPOR G1251T mutation results in the replacement
of a glutamate residue by a stop codon at amino acid 393. Differently from polycythemia vera, EPOR G1251T CD34
+ cells
proliferate and differentiate towards the erythroid phenotype in the presence of minimal amounts of EPO. Moreover, the
affected individuals show a 20-fold increase of circulating endothelial precursors. The analysis of erythroid precursor
membranes demonstrates a heretofore undescribed accumulation of the truncated EPOR, probably due to the absence of
residues involved in the EPO-dependent receptor internalization and degradation. Mutated receptor expression in EPOR-
negative cells results in EPOR and Stat5 phosphorylation. Moreover, patient erythroid precursors present an increased
activation of EPOR and its effectors, including Stat5 and Erk1/2 pathway.
Conclusions/Significance: Our data provide an unanticipated mechanism for autosomal dominant inherited polycythemia
due to a heterozygous EPOR mutation and suggest a regulatory role of EPO/EPOR pathway in human circulating endothelial
precursors homeostasis.
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Introduction
Erythropoietin (EPO) is a key cytokine, produced mainly in
peritubular renal cells but also in the liver, that modulates the
growth, survival, and differentiation of erythroid progenitor cells,
leading to tight control of red blood cell production. Its receptor
(EPOR) is a homodimeric transmembrane protein of 508 amino
acids in humans (507 in mice) that belongs to a superfamily of
cytokine receptors, which includes receptors for GM-CSF and
interleukin-3 and -6 [1]. As with other members, the extracellular
ligand binding region of EPOR contains four conserved cysteine
residues and a WSXWS motif.
The human EPOR gene is located on chromosome 19 and
contains eight exons [2 and references therein.] The first five exons
encode the extracellular region that embraces the high EPO
affinity of A, B, D helix site-1 and the low Epo affinity of A, C helix
site-2 interactions, with 7 beta-strand bipartite binding sites in
appositioned EPOR dimmers. Exon 6 encodes the membrane
spanning domain, while the two intracellular receptor domains are
encoded by exons 7 and 8 [2 and references therein].
The receptor does not possess any kinase activity, but its
intracellular region binds to JAK2 tyrosine kinase that is essential
for EPO signaling. EPOR engagement stimulates JAK2 phos-
phorylation at Y1007/1008 residues [3]. In turn, activated JAK2
(in concert with other kinases) phosphorylates eight conserved
tyrosines in cytoplasmic domain [4]. These phosphotyrosine (PY)
sites of EPOR function as docking sites for the binding of
molecules containing SH2/SH3 motifs to EPOR. One subset of
PY site–recruited factors (PY 402, 430, 432) coordinates negative
feedback of EPO signaling. EPO’s positive signals are determined
PLoS ONE | www.plosone.org 1 August 2010 | Volume 5 | Issue 8 | e12015by different PY site-recruited factors (PY 344, 426, 461, 465, 480)
[4]. It is currently assumed that two boxes at the membrane-
proximal region of the EPOR cytoplasmic domain and Y344 are
the major positive motifs and that the activation of Stat5 is central
for EPOR function [5]. However, since these conclusions have
been mainly reached in animal models or in non-erythroid
artificial in vitro cell systems, these assumptions await confirmation
in the physiological human environment.
In the mouse spleen and bone marrow, EPOR engagement
regulates erythropoiesis [6], while the EPO importance in brain
development and, possibly, in endothelial precursor mobilization
has been suggested [7,8]. Moreover, EPO/EPOR signaling, at
least in the mouse, seems to have a protective role in myocardial
ischemia/infarction and in pulmonary hypertension [7,8]. How-
ever, the notion that EPOR plays non-erythropoietic function has
been recently strongly challenged [9]. It is also to underscore that
erythropoiesis is not equivalent in mice and humans. Thus, a
transgenic mouse with the mouse EpoR gene replaced with human
polycythemia-causing EPOR, with the truncated deletion in the
intracellular region just before tyrosine 410, was polycythemic
[10]. Conversely, mice expressing a truncated mouse EpoR were
not polycythemic [11]. This emphasizes that results obtained in
animal models, albeit important for the understanding of gene
function, might not be always extrapolated to human physiology
and/or human diseases.
EPOR has been reported to be expressed not only in erythroid
precursors but also in other cells and organs, including endothelial
cells, the brain, and kidneys [8,12,13]. These findings have been
obtained by immunohistochemical studies, as well as with highly
sensitive reverse transcription-polymerase chain reaction [12,13].
However, strongly concerns have been raised about the specificity
of antibodies used to detect EPOR [14], and the presence of
EPOR transcripts is not sufficient to demonstrate the occurrence
of an active receptor and its downstream pathways. Therefore, the
distribution of functional EPOR in human tissues still remains
controversial.
The interest in EPOR has recently exploded following reports of
the presence of the receptor on cancer cells with detrimental
clinical outcome after EPO treatment [15,16]. Although the role
of EPO in cancer progression remains controversial [17], the
possible EPOR-dependent proliferation of neoplastic cells high-
lights the importance of accurate delineation of human EPOR
physiology.
A small number of EPOR mutations have been described, which
are associated with primary familial and congenital polycythemias
(PFCPs) [18–25]. These patients show, low serum EPO levels,
normal haemoglobin oxygen affinities, and erythroid progenitors
that exhibit EPO hypersensitivity [26]. Clinically, PFCP patients
may present with symptoms ranging from headaches, dizziness,
epistaxis, exertional dyspnea to pruritis after bathing [27].
Moreover, thrombotic and hemorrhagic events with premature
morbidity and mortality have been reported [28,29]. Clinical
symptoms are effectively relieved by phlebotomy, but the
increased risk of cardiovascular morbidity is not ameliorated by
maintaining a normal hematocrit [30]. However, detailed cellular
and molecular explanations of the mutated EPOR pathophysiol-
ogy of these patients have not been obtained.
We investigated the EPOR gene in a family with dominant
polycythemia and found a mutation resulting in a receptor lacking
most of the cytoplasmic domain. We demonstrated a marked
increase of EPOR protein on the membrane of erythroid
progenitors and report its role in deregulating CD34
+ cells
proliferation and differentiation. We also describe a strong increase
of circulating endothelial precursors in the affected subjects.
Results and Discussion
The propositus (P1, Figure 1A) was referred from a group of
114 patients included in the Italian registry of congenital
erythrocytosis/polycythemia. The index patient is a 14-year-old
child who, at 7 years of age, was evaluated for persistent headaches
and leg muscle cramps. He had an elevated hemoglobin level and
hematocrit (21 g% and 66%, respectively), no splenomegaly, and
normal blood pressure. White blood cell and platelet counts were
normal. The patient’s 41-year-old father (P3) presented at 19 years
of age with elevated values for hemoglobin and hematocrit
(20.1 g% and 64%, respectively) and normal white-cell and
platelet counts. He suffered from persistent headaches and had a
mild mitral valve insufficiency and a liver steatosis. Both P1 and P3
were regularly phlebotomized with symptomatic relief. The
propositus’ paternal grandfather was also reported as ‘‘polycythe-
mic’’. He died at 55 years of age of liver cirrhosis. The hemoglobin
level and hematocrit were also elevated in the paternal uncle (P4)
and his daughter (P5), but these patients have scarce clinical
symptoms and, thus, were not phlebotomized. The serum EPO
was ,3 mU/mL (normal range, 4 to 32 mU/mL) in all the four
polycythemic family members, while hemoglobin oxygen affinities
(p50) were normal.
All patients were screened for defects in the Von Hippel-Lindau, HIF-
1alpha, HIF-2alpha, PHD1-3, JAK2,a n dEPOR genes. No mutations
were found in the Von Hippel-Lindau, HIF-1alpha, HIF-2alpha, PHD1,
PHD2, PHD3, and JAK2 genes. However, a heterozygous GRT
change at nucleotide 1251 in exon 8 of the EPOR gene was detected in
the index patient (Figure 1A). This novel mutation (EPOR G1251T)
caused the replacement of a glutamic acid residue with a stop codon at
amino acid 417, which corresponds to residue 393 of the mature
receptor. The EPOR G1251T mutation segregated with the
polycythemic status, as demonstrated by the EPOR analysis of other
family members (Figure 1B). This genetic change resulted in the
synthesis of a truncated receptor lacking the cytosolic tyrosines
subjected to phosphorylation, except Y344.
Since our patients had a very low serum EPO level, we
investigated the growth and differentiation of erythroid precursors
in the absence of exogenously added EPO with normal and
polycythemia vera (PV) cells used as controls. PV cells were chosen
as their erythroid precursors are EPO hypersensitive.
In a first set of experiments, the proliferation of erythroid
precursors was investigated by employing liquid cultures of
mononuclear cells as previously reported [31]. The concentration
of EPO in these experiments, due to the fetal bovine serum present
in the culture medium, was calculated to be 0.4 mU/mL, namely
about ten-fold lower that the patient EPO serum and 7–8 thousand-
fold lower than the amount used in in vitro erythroid precursors
cultures (i.e. 3 U/mL). We observed that the peripheral erythroid
EPOR G1251Tprecursors grew2–3 times faster than cells from PV.
Thus, the cells from EPOR G1251T patients increased about 16-
fold after 12 days compared to a 6-fold increase of the PV subjects
(Figure 2A). Under the same condition, normal erythroid
precursors underwent apoptosis. Significant growth rate differences
between EPOR G1251T and PV patients were evident at all
examined time-periods (Figure 2A).
Glycophorin A expressing cells were analyzed after 14 days of
proliferation without exogenously added EPO (i.e. at 0.4 mU/mL
EPO concentration) as reported in Figure 2B. The percentages of
EPOR G1251T cells and PV patients that expressed the erythroid
marker were 5365% and 1362%, respectively.
When, the same experiment was performed in the presence of
3 U/mL EPO, no significant difference of erythroid maturation
was observed (Figure 2B).
Primary Polycythemia and EPOR
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cells prepared from EPOR G1251T and PV patients to highlight
phenotypic differences of the early hematopoietic precursors from
these two forms of erythrocytoses. As shown in Figures 2C and
2D, while a significant percentage (51.564.1%) of peripheral
CD34
+ cells from P1 (grown for 14 days without exogenously
added EPO) expressed glycophorin A, the antigen was not
detectable in peripheral CD34
+ cells from PV patients cultured
under the same conditions.
When CD34
+ cells were cultured on soft agar with minimal
EPO (0.4 mU/mL) marked differences in the number and size of
colonies were observed after 14 days. As shown in Figure 2E,
CD34
+ cells of P1 formed large visibly hemoglobinized colonies
while only few small, pale, poorly hemoglobinized colonies were
seen in CD34
+ cells cultures from PV patient (Figure 2E).
Identical findings were obtained with CD34
+ cells from P3, P4 and
P5 patients (data not reported). We also prepared the DNA from
the largest colonies of P1 and examined the status of the EPOR
gene. No gene conversion was observed and the heterozygosity of
EPOR G1251T was maintained.
Finally, no difference in the number and size of colonies was
observed after 14 days when CD34
+ cells from control subjects,
PV patients or PFCP patients were cultured on soft agar in the
presence of 3 U/mL EPO (data not reported).
It has been suggested, although still debated, that EPO/EPOR
pathway plays a role in the endothelial cell homeostasis. Thus, we
analyzed the number of circulating endothelial precursors (CEPs)
of all PCFP patients by flow cytometry. CEPs were identified as
CD45
dim/CD34
+/VEGFR2
+ peripheral cells [32]. Figure 3A
depicts an example of the flow cytometry analysis performed.
CEPs were 710685 cells/mL in the EPOR-mutated subjects
(Figure 3B), which is about 20-fold higher than the CEPs in
the age-matched controls. The CEP level of 3 examined PV
patients, all having a classical JAK2 mutation (JAK2V617F), were
similar to the CEPs content of EPOR G1251T subjects
(Figure 3B).
Figure 1. EPOR mutation and pedigree of the polycythemic family. Panel A. The panel shows nucleotides 1242–1270 (exon 8) of the EPOR
gene. A heterozygous G1251RT mutation was detected in the propositus P1. The same mutation was verified in all the subjects affected by
erythrocytosis (P1, P3, P4, and P5). Panel B. Pedigree of the family with dominant familial erythrocytosis is shown. Squares represent males, circles
represent females, and Ps represent the subjects that were genotyped. P1, P3, P4, and P5 are the subjects affected by congenital polycythemia.
doi:10.1371/journal.pone.0012015.g001
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+cells from the affected patients. Panel A. Growth curve of blood
erythroid precursors from the the four EPOR G1251T subjects, three subjects affected by PV (JAK2 V617F homozygotes), and three healthy subjects.
Erythroid precursors were grown from peripheral mononuclear cells as described (Migliaccio et al., 2002) without adding recombinant EPO. The
estimated concentration of EPO in the growth medium was about 0.4 mU/mL. Data represent mean 6 SEM (n=3 per cell type), and are
representative of 3 experiments. Panel B. The graphic reports the percentage of BFU-E cells (evaluated by glycophorin A expression after 14 days
growth) in liquid cultures of erythroid precursors from the P1 patient and two PV patients (JAK2 V617F homozygotes). The cells were cultured in the
absence of exogenously added EPO. Data represent mean 6 SEM (n=3 per cell type), and are representative of 2 experiments. Panel C. Fluorescent
activated cell scanner (FACS) analysis of liquid cultures of peripheral purified CD34
+ cells grown for 14 days in with minimal EPO. The erythroid
precursors were prepared from the P1 subject and from a patient affected by PV associated with a classical JAK2 mutation (JAK2 V617F homozygote).
GlyA
+ means glycophorin A positive cells. The results are representative of three independent experiments that gave superimposable results. Panel
D. FACS analysis of samples shown in panel C. The panel reports the analysis of GlyA levels in cells plotted versus forward scatter. Panel E. Peripheral
CD34
+ cells were growth on soft agar in the absence of EPO. The images report the features of colonies from the P1 subject (b, d) or from a subject
affected by PV (JAK2 V617F homozygote) (a, c). The results are representative of four independent experiments that gave superimposable results.
doi:10.1371/journal.pone.0012015.g002
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+ cells
and the increased levels of peripheral CEPs prompted us to
investigate EPOR mRNA and protein levels during CD34+
erythroid differentiation in vitro.
The expression of both EPOR mRNA alleles in erythroid
precursors from the four patients was evaluated by semiquantita-
tive PCR (Figure 3C) and real-time PCR (Figure 3D) after 7
days of cultures in the presence of EPO. Both methods
demonstrated that mutant EPOR G1251T and wild type EPOR
alleles were expressed at similar levels and that the total EPOR
transcript of the EPOR G1251T erythroid precursors corresponds
to the EPOR mRNA of erythroid precursors of an healthy subject
(Figure 3D). This is in accord with results of a previous study on
PFCP, although different PCR methods were employed [19].
The realtime PCR approach was also employed to evaluate the
expression of the two EPOR alleles of primary cultures of CEPs
(P1, P3 and P5 patients). The results obtained are identical to those
obtained on the eythroid precursors in that both mutant EPOR
G1251T and wild type EPOR alleles were expressed at similar
levels (data not shown). It is to underline that CEPs EPOR mRNA
is easily detectable and that it corresponds to about 10% of EPOR
mRNA of erythroid precursors, the cells that probably express the
major amount of this transcript in the human body (Figure 3E).
In conclusion, the evaluation of levels of the two EPOR mRNA
forms indirectly argues that similar amounts of normal and
truncated protein receptors may exist in EPOR-expressing cells as
reported in previous studies on PCFC.
In order to verify this conclusion, the status of the EPOR
protein on the membrane of erythroid precursor cells was
investigated. The lack of specific antibodies against the N-terminal
region of EPOR has so far hampered direct biochemical analyses
of the EPOR peptide. Recently, we have identified and
characterized in detail a highly specific antiserum against the
extracellular domain of the receptor [33]. To rule out nonspecific
crossreactivity by the EPOR antibody and identify the molecular
weight of the truncated receptor, we prepared the recombinant
wild type and mutated EPOR proteins with an in vitro transcription
and translation (IVTT) kit. Moreover, we expressed the native and
truncated EPOR in a human EPOR–negative cell line, i.e. K562
cells, for further positive controls. As shown in Figure 4A, the
antiserum against the extracellular domain recognized the wild
type EPOR form at 66–67 kDa and the mutated EPOR G1251T
form at about 52–53 kDa.
When the isolated cell membrane fractions from the patient
were analyzed, we observed the presence of a strong band at the
mutated form and a very faint band at the wild type EPOR. The
finding was observed in either CD34
+ cells grown for 7 and 10
days in the presence of 3 U/mL EPO (Figure 4B) or in cells
cultured for 7 days in minimal EPO level (0.4 mU/mL)
(Figure 4C). The analysis of membrane fractions from control
erythroid precursors showed a barely detectable band of the wild
type protein.
It is to underline that when CD34
+ cells (both from controls or
PCFP subjects) were growth in the presence of EPO they showed
similar differentiation as demonstrated by their glycophorin A
content (Figure 4B). Thus, changes in the truncated EPOR
protein levels cannot be ascribed to difference in cellular
populations due to variable degree of differentiation.
The unanticipated observation that, even in the presence of
high EPO, the lack of a large part of the receptor cytoplasmic
domain results in the cell membrane accumulation of mutated
EPOR, suggested that the truncated receptor has a slower
membrane internalization/degradation and an increased half-life
due to the absence of sequences required for receptor internali-
zation and degradation.
In order to confirm this hypothesis, we incubated CD34
+ cells
with a proteasome inhibitor, i.e. LLnL, that has been previously
reported to induce membrane EPOR accumulation by hampering
the receptor removal [34]. Thus, CD34
+ cells were cultured for 7
days with EPO and, then, treated for 4 hours with the proteasome
inhibitor. As shown in Fig. 4D, LLnL treatment causes the
increase of wild-type EPOR while scarce change of mutated
EPOR level was observed. The finding suggests that the turn-over
time of the two forms was considerably different, being the
mutated form remarkably more stable.
The observed difference of receptor turn-over is also in accord
with data obtained in UT-7 cells, showing EPOR internalization
and removal requires ubiquitination of the receptor’s C-terminal
region [34]. In particular, members of the beta-Trcp family have
been shown to participate in the E3 ligase activity responsible for
EPOR ubiquitination [35]. Beta-Trcp binds to Ser 462 within the
intracellular part of the receptor and contributes to EPOR
ubiquitination in the presence of the hormone. The ubiquitination
mediated by beta-Trcp is a crucial signal for the C-terminus
degradation of EPOR because the point mutation of Ser 462 to
Ala blocks EPOR targeting to the proteasome, thereby leading to
sustained activation of EPOR(S462A). It is interesting that BaF3
cells, expressing a mutated EPOR unable to bind beta-Trcp, are
hypersensitive to EPO, suggesting beta-Trcp-mediated ubiquitina-
tion represents a negative modulator of EPO-induced cellular
Figure 3. Analysis of circulating endothelial precursors from polycythemic patients. Panel A. Evaluation of circulating endothelial
progenitor cells by cell phenotype. The panel reports the flow cytometric analysis of circulating endothelial precursors from patient P1, a) shows the
gate made to eliminate platelets and cell debris; b) reports the gate for eliminating apoptotic/necrotic cells (7-AAD positive); c) shows the gate for
enumerating CD34
+ cells; d) indicates the gate made to enumerate CD34
+ and CD45
neg/dim cells; e) reports the negative control; and f) is the final
gate enumerating CD45
neg/dim, CD34
+, and VEGFR2
+ circulating endothelial precursors. The results are representative of several (.10) independent
experiments that gave superimposable results. Panel B. The panel shows the number of circulating endothelial precursors of normal subjects, the
four EPOR G1251T patients, and three subjects affected by PV. The results represent the mean (bar, SD) of 4 independent evaluations (each performed
in duplicate) of the subjects analyzed. Panel C. The panel reports a semiquantitative evaluation of the expression of EPOR alleles in erythroid
precursors from subjects of the family investigated. Total RNA was prepared from erythroid precursors after 7 days of growth (in the presence of 3 U/
mL EPO) and retrotranscribed to cDNA. Then, PCR was performed employing primers specific for the two alleles (ie the wild-type and mutated). The
antisense primer of the mutated allele inserted a restriction site for NdeI in the amplified product that allowed distinction between the normal and
mutated allele. After the PCR reaction, the mixtures were digested with the Ndel enzyme. The 167 bp product is derived from the wild-type transcript
while the 144 bp product is from the mutated EpoR mRNA form. The figure is representative of 5 experiments. Panel D. Total RNA (see panel C) was
employed to evaluate the content of EPOR alleles (wild type and EPOR G1251T) by realtime PCR. Expression was normalized to beta-actin and
expressed as a percentage of wild type EPOR RNA from a control subject. Each bar represents the mean value 6SD. The figure is representative of 4
experiments. Additional details are reported in the text. Panel E. Total RNA were prepared from CD34+ cells (grown 7 days in the presence of EPO)
and circulating endothelial precursors. Then, RNA was employed to evaluate the content of EPOR transcript by realtime PCR. Expression was
normalized to beta-actin and expressed as a percentage of wild type EPOR RNA from CD34+ cells Each bar represents the mean value 6SD. The figure
is representative of 5 experiments.
doi:10.1371/journal.pone.0012015.g003
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(from the left to right): i) UT-7 cells; ii) untransfected K562 cells (Con); iii) wild-type EPOR transfected K562 cells (WT-EPOR); iv) mutated EPOR
transfected K562 cells (MutEPOR); v) in vitro transcription/translation (IVTT) control mixture; vi) in vitro transcribed and translated wild-type EPOR, and
vii) in vitro transcribed and translated mutated EPOR. K562 cells were transfected employing pMT21 plasmids encoding wild-type or mutated EPOR,
while pcDNA3.1 plasmids were employed in the IVTT experiments. UT-7 cells were employed since these cells contain abundant amounts of wild-
type EPOR (Della Ragione et al., 2007). Immunoblotting was performed with the antiserum against the N-end of EPOR. The bottom image is the filter,
before immunoblotting, and colored with Red Ponceau. The image confirms equal loading of membrane proteins (lanes 2,3 and 4) and IVTT assay
mixtures (lanes 6, 7 and 8). The immunoblotting is representative of 4 experiments. Panel B. The image on the left reports the immunoblotting
analysis of membranes from the following samples (from left to right): I) peripheral CD34
+ cells from a healthy subject (Con) grown for 7 days with
EPO (3 U/mL); ii) peripheral CD34
+ cells from patient P1 (MutEPOR) growth for 7 days with EPO (3 U/mL); iii) peripheral CD34
+ cells from a healthy
subject (Con) grown for 10 days with EPO (3 U/mL); and iv) peripheral CD34
+ cells from patient P1 (MutEPOR) grown for 14 days with EPO. The
immunoblotting on the right reports cell membranes from K562 cells cotransfected with the wild-type and mutated EPOR pMT21 plasmids as
standard for the two EPOR forms. The immunoblotting was performed with the antiserum against the N-end of EpoR. The filter was also re-analyzed
by antibodies against glucophorin A (immunoblotting at the center). The bottom image was taken to the filter colored with Red Ponceau before
immunoblotting. The image confirms the equal loading of membrane proteins. The image is of 3 experiments. Panel C. The image on the left reports
the immunoblotting analysis of membranes from the following samples (from left to right): i) peripheral CD34
+ cells from a healthy subject (Con)
cultured for 7 days without minimal EPO (0.4 mU/mL); ii) peripheral CD34
+ cells from patient P1 (MutEPOR) cultured for 7 days without EPO. The
immunoblotting at the right reports cell membranes from K562 cells cotransfected with both the wild-type and mutated EPOR pMT21 plasmids. The
immunoblotting was performed using the antiserum against the N-end of EPOR. The bottom image was taken to the filter colored with Red Ponceau
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strong EPO hypersensitivity of the erythroid precursors possessing
the truncated receptor. In addition, the mechanism is in accord
with a recent investigation demonstrating that phosphorylated
Y429, Y431, and Y479 in the EPOR cytoplasmic domain bind
the p85 subunit of PI3 kinase on EPO stimulation and individually
are involved in mediating EPO-dependent EPOR internalization
[36].
In order to highlight the biochemical consequences of the
truncated receptor accumulation, the possibility that the two
EPOR isoforms might interact to form a heterodimer was
investigated. Thus, the truncated and wild-type EPORs were
overexpressed in K562 cells and membrane proteins were
incubated with an antiserum directed against the C-terminus.
The immunoprecipitated materials were then analyzed with the
antiserum directed against the N-terminus and the occurrence of
both the native and the truncated proteins was shown. The result
obtained demonstrated that the two EPOR isoforms might
undergo heterodimerization (Figure 4E). However, although
the input material contained equal amounts of the two EPOR
isoforms and almost all the wild-type receptor was immunopre-
cipitated, a large excess of the truncated receptor remained in the
supernatant (Figure 4E). This argues that the wild-type receptor,
and thus the truncated EPOR, preferentially form homodimers.
Therefore, we evaluated whether high levels of homodimers of
truncated EPOR might result in excessive EPO signaling and/or
in an EPOR autoactivation event. To validate these hypotheses,
the truncated EPOR was overexpressed in K562 cells and the
effect on receptor autophosphorylation and Stat5 phosphorylation
was evaluated. As shown in Figure 5A, transfection of the
truncated receptor induced a number of biochemical changes (i.e.
receptor autophosphorylation and STAT5 phosphorylation), even
in the absence of exogenously added EPO, suggesting the
possibility of autoactivation and/or hypersensitivity of receptor.
Since these events occur at level of truncated EPOR similar to
those observed in erythroid precursors cells, it is likely that these
receptor features might be observed in these cells.
Then, we investigated the activity of the EPOR-JAK2-STAT5
pathway in CD34
+ from control and EPOR truncated subjects,
grown for 7 days with or without exogenously added EPO. As
shown in Figures 5B and 5C, in the presence of 3 U/mL EPO,
we found a clear increase of receptor and STAT5 phosphoryla-
tion. Although we were unable to directly demonstrate the
phosphorylation of the truncated EPOR in the absence of the
cytokine, we observed, under this condition, the activation of
EPOR-dependent pathway by detecting STAT5 phosphorylation
in CD34
+ cells cultured without EPO (Figure 5D). The finding
was also confirmed by the activation of Erk1/2, which was
significantly increased in cells from EPOR truncated subjects,
grown for 7 days with EPO (Figure 6A). In the presence of
minimal amounts EPO, we also found increased Erk1/2
phosphorylation, which suggests greatly augmented activity of
the receptor (Figure 6B).
An increase of p27
Kip1 (an inhibitor of cell cycle progression) has
been reported during erythroid differentiation of experimental
models of erythropoiesis [37]. As reported in Figure 6C, we also
observed an increase of p27
Kip1 on different days of CD34
+
growth in the presence of EPO. Intriguingly, in cells grown for 7
days with EPO, we found an increase of p27
Kip1 in cells from the
EPOR G1251T patient compared with cells of the control subject
(Figure 6D).
In conclusion, in this study, we report that the gain-of-function
EPOR G1251T mutation results in a marked alteration of growth
anddifferentiationofhumanCD34+ andinanincreaseoferythroid
progenitors’ surface EPOR peptide. Moreover, we observed a
profound increase of circulating endothelial precursors in the
affected subject. Our data elucidate how the heterozygous EPOR
gene mutation causes a dominantly inherited polycythemia
phenotype and erythroid progenitors’ EPO hypersensitivity. We
demonstrate for the first time that, although both alleles of the
patients were transcribed atsimilar rates inerythroidprecursors and
roughly the same as the normal alleles of healthy subjects, the
truncated receptor accumulates at very high levels on cellular
membranes. This leads to augmented activation of growth and
erythroid differentiation of CD34+ observable at EPO levels lower
that that necessary to activate CD34+ of PV patients. EPO
hypersensitivity might be due to both: i) the remarkable accumu-
lation of truncated EPOR and its autoactivation, and ii) loss of the
negative regulatory domain of the EPOR G1251T mutant.
The CD34+ cells proliferation and differentiation, observed
without exogenous EPO, also demonstrated the EPOR sequence,
including Y344, is sufficient to activate the proliferation and
differentiation of human erythroid precursor cells. In the same
context, the truncated EPOR-dependent activation of Erk2
suggests Erk2 may not require PY480 or phospholipase C-gamma
for its activation, as reported by others [2].
The importance of the EPO-EPOR system in erythropoiesis
and vasculogenesis was established using mutant mice lacking
either the Epo or EpoR gene [38]. Although these observations are
consistent with participation of EPOR in vasculogenesis, the
precise contribution of EPOR function in nonhematopoietic tissue
remains to be defined, and is the object of intense debate. It has
been described that EPO administration can increase the number
of CEPs in healthy subjects. It has been postulated that this
increase might be due to an EPO-derived stimulation of cytokine
production. Our observation that the EPOR G1251T patients with
activated EPO-EPOR signaling have an increased number of
CEPs suggests the CEPs increase may be due to a constitutive
EPO receptor activation in this population. An increase in
circulating CD34
+ cells has been described in patients carrying
before immunoblotting. The image confirms the equal loading of membrane proteins. The immuniblotting is representative of 3 experiments. Panel
D. Peripheral CD34
+ cells from patient P1 were cultured for 7 days with EPO. Then, the cells were added with (or without) 50 mM LLnL for 4 hours.
Finally, cell membranes were prepared and analyzed fot EPOR content. The immunoblotting was performed with the antiserum against the N-end of
EpoR. The immunoblotting on the left reports cell membranes from K562 cells cotransfected with the wild-type and mutated EPOR pMT21 plasmids
as standard for the two EPOR forms. Panel E. K562 cells were cotransfected with the wild-type and mutated forms of EPOR. Then, K562 cell
membranes (Input) were immunoprecipitated with an antiserum directed against the EPOR C-end (IP C-end). Finally, the immunoprecipitated
materials (IP) and the supernatant (IP Sup) of the reaction were analyzed with the antiserum directed against the EPOR N-terminus (WB N-end). The
blot reports the following samples (from the left): i) IVTT wild-type EPOR; ii) membranes from cotransfected K562 cells (Input); iii) the
immunoprecipitated materials (IP); iv) the supernatant of the immunoprecipitation (IP Sup); v) IVTT reaction of mutated EPOR. Note that the asterisk
represents the signal due to the heavy chain of antibodies employed in the immunoprecipitation. The signal is immediately up to the band of the
truncated receptor. Two different times of exposition are reported (1 minute and 5 minutes) to demonstrate the difference in the ratio of wild type/
mutated forms in the input and in the supernatant. The input sample is 1/4 of the supernatant sample. The immunoblotting is representative of 3
experiments.
doi:10.1371/journal.pone.0012015.g004
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[39]; to our knowledge, this is the first report demonstrating an
increased number of endothelial precursors in the circulation of
patients with gain-of-function EPOR mutations. It remains to be
established whether this is due to increased CEP production,
increased CEP mobilization, or both mechanisms.
Materials and Methods
Mutational analysis and evaluation of EPOR mRNA
isoforms
Blood samples were obtained from the index patient, his parents
and relatives, from healthy controls, and from four patients with
Figure 5. EPOR phosphorylation and STAT5 activation in erythroid cells expressing wild type or mutated EPOR. Panel A. K562 cells
were transfected with the mutated form of EPOR. After 3 days of growth in the absence of exogenously added EPO, K562 cell membranes and total
cell extracts were prepared. (On the left) The membranes were analyzed with antibodies against EPOR N-end or against phosphotyrosine. A
phosphotyrosine signal occurs only in the transfected cells and at the molecular weight of the mutated EPOR signal. (On the right) Cell extracts was
analyzed for STAT5 and phosphoSTAT5 levels by means of specific antibodies. The immunoblotting is representative of 3 experiments. Panel B.
Purified CD34
+ cells from a control and P1 subject were grown for 7 days in the presence of EPO. Then, cell membranes were prepared and EPOR
content and phosphorylated form were evaluated as in panel A. The immunoblotting is representative of 3 experiments. The data are are
representative of 3 experiments. Panel C. Purified CD34
+ cells from a control and P1 subject were grown for 7 days in the presence of EPO. Then, cell
extracts were prepared and STAT5 and its phosphorylated form were analyzed as in panel A. The data are are representative of 3 experiments. Panel
D. Purified CD34
+ cells from a control and P1 subject were grown for 7 days in minimal EPO (0.4 mU/mL). Then cell extracts were prepared and STAT5
and phosphorylated fprm were analyzed as in panel A. Note: We were unable to evidentiate the phosphorylation of mutated EPOR in CD34+ cells
grown in minimal EPO. This was probably due to the scarce amount of material available. However, differences in STAT5 activation between the
control cells and cells from the patient were evident in panel D.
doi:10.1371/journal.pone.0012015.g005
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written informed consent on entering the study, which was
approved by the research ethics committee of Second University of
Naples, Italy, and the study was conducted according to the
Declaration of Helsinki. DNA and RNA were prepared by
standard methods. To screen for mutations of the EPOR gene,
exons 7 and 8 with exon-intron boundaries were amplified by
PCR using the following method and primers:
PCR was performed with 30 cycles of denaturation (1 min, 94uC),
annealing (1 min, 60uC), and elongation (1 min, 72uC) and the
amplified products were analyzed on 2% agarose gels, stained with
ethidium bromide. Oligonucleotides used to amplify either exon 7
(362 bp) or 8.1 (301 bp) and exon 8.2 (333 bp) were as follows:
exon 7 forward: 59-GCCTCTATGACTGGGAGTGG-39
exon 7 reverse: 59-GCGCTCTGAGAGGACTTCC-39
exon 8.1 forward: 59-GCCTGGGCTTCCCTGCTTCTTGC-39
exon 8.1 reverse: 59-TTCGAGGCCAAAGCAGATGAGCA-39
exon 8.2 forward: 59-TATCTGGTGCTGGACAAATGGTT-39
exon 8.2 reverse: 59-CTGCAGCCTGGTGTCCTAAGAGC-39
The amplified products were purified and sequenced.
Two independent methods were developed for quantifying the
expression of the EPOR alleles (ie wild-type and mutated forms).
First, we designed a primer incorporating a mismatched base,
corresponding to the allele with the G1251T mutation, to engineer
a restriction site for NdeI in the PCR product. After the PCR
reaction, the assay mixture was digested with the NdeI enzyme
(Invitrogen, Carlsbad, CA, USA) and only the product from the
mutated allele was digested. The mutated allele yielded 2 fragments
of 144 bp and 23 bp, and wild type an uncut 167 bp band.
Second, a TaqMan assay was performed using the iCycler iQ
Real-Time PCR Detection System (Bio-Rad Laboratories, Hercu-
les,CA).Wesynthesized two probes,one specificforthedetectionof
thewild-typeallele,labeled with a FAMdye,and onespecificforthe
mutated allele, labeled with a HEX dye. Each incorporated Locked
Nucleic Acids (Sigma-Aldrich, Sigma Chemical Company, St.
Louis, MO, USA), a nucleic acid analogue that contains a 29-O, 49-
C methylene bridge. This bridge restricts the flexibility of the
ribofuranose ring and locks the structure into a rigid C3-endo
conformation, conferring enhanced hybridization performance and
markedly increased stability. The amount of each expressed allele
was standardized using wild-type and mutated EPOR pcDNA3.1
plasmids. Further details on the methods, as well as on the primers
employed, will be provided on request.
Erythroid precursor cultures
Liquid cultures of erythroid precursors from peripheral blood
were prepared by two methodologies. The first utilized peripheral
blood mononuclear cells as a source of erythroid progenitors [31],
while the second employed the peripheral blood CD34+ cells as a
source of progenitors [40]. Soft agar colony assays were performed
as described [41]. The colonies were scored after 0, 7, and 14 days
and their images captured after 14 days.
Circulating endothelial cell evaluation
Circulating endothelial precursors were measured by six-color flow
cytometry as previously described [32]. Primary cultures of circulating
endothelial precursors were prepared as previously described [32].
Figure 6. Transduction pathway status of erythroid precursors. Panel A. Cytosolic extracts of CD34
+ cells, cultured for 7 days in the presence
of EPO, were prepared from a healthy subject and patient P1. Then, samples were analyzed for Erk1/2 and phospho Erk1/2 content. Panel B.
Cytosolic extracts of of CD34
+ cells, cultured for 7 days in the absence of exogenously added EPO (0.4 mU/mL EPO), were prepared from a healthy
subject and patient P1. Then the samples were analyzed for Erk1/2 and phospho Erk1/2 content. Panel C. CD34
+ cells from a healthy subject were
grown for up to 14 days in the presence of EPO. Aliquots of cells at days 0, 7, and 14 were removed and cell extracts were prepared. Then, the
samples were analyzed for p27
Kip1 content by immunoblotting. Panel D. CD34
+ cells from a healthy subject and patient P1 were grown for 7 days in
the presence of EPO and cellular extracts were prepared. Then, samples were analyzed for p27
Kip1 content.
doi:10.1371/journal.pone.0012015.g006
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The wild-type coding sequence of human EPOR, cloned into
the pMT21 expression vector, was kindly provided by Dr. A.
D’Andrea. The sequence was mutagenized at the 1251 (GRT)
position, and the wild-type and mutated EPOR sequences were
subcloned into the pcDNA3.1 plasmid. These pcDNA3.1 vectors
were used to prepare in vitro the respective proteins by TNT kits
(Promega Italia, Milan, Italy). pMT21 plasmids containing the
wild-type and mutated EPOR coding sequences were transiently
transfected in the human K562 cell line (a negative erythroleu-
kemic EPOR cell line) by standard procedures [33,42]. The
treatments with N-Ac-Leu-Leu-norLeucinal (LLnL) (Merck Bio-
sciences, Darmstadt, Germany) were performed as reported in
[34]. Cell membranes were prepared with the Qproteome Cell
Compartment Kit (Qiagen, Valencia, CA, USA), while cytosol
and nuclei were obtained using NE-PER Nuclear and Cytoplas-
mic Extraction Reagents (Pierce Biotechnology, Rockford, IL)
[33]. Immunoblotting procedures and immunoprecipitation ex-
periments were essentially performed as described [33,42].
The following antibodies were employed in the immunoblotting
and immunoprecipitation experiments. Goat polyclonal antiserum
directed against the extracellular domain of EPOR was from
Abcam (Abcam, Cambridge, MA); rabbit polyclonal anti C-end of
EPOR, Stat5, and phospho-Erk1/2 and mouse monoclonal
antibodies anti Erk1/2 and anti-phosphotyrosine (PY20) were
from Santa Cruz Biotechnology (Santa Cruz Biotechnology, Santa
Cruz, CA); mouse monoclonal antibodies anti phospho-Stat5 were
from Upstate Biotechnology (Upstate Biotechnology, Charlottes-
ville, VA); monoclonal antibodies against p27
Kip1 were from
Transduction Laboratories (Transduction Laboratories Lexington,
KY).
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